Get the Stockscreener App
4.18
0.24%
0.010
Pre-market:
4.16
-0.02
-0.48%
Briacell Therapeutics Corp stock is traded at $4.18, with a volume of 193.62K.
It is up +0.24% in the last 24 hours and down -41.70% over the past month.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
See More
Previous Close:
$4.17
Open:
$4.13
24h Volume:
193.62K
Relative Volume:
0.52
Market Cap:
$25.96M
Revenue:
-
Net Income/Loss:
$-29.01M
P/E Ratio:
-0.0864
EPS:
-48.3535
Net Cash Flow:
$-29.34M
1W Performance:
-2.79%
1M Performance:
-41.70%
6M Performance:
+563.49%
1Y Performance:
+3.21%
1-Day Range:
$4.05
$4.235
1-Week Range:
$4.05
$4.4981
52-Week Range:
$0.61
$14.68
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
4.18 | 25.90M | 0 | -29.01M | -29.34M | -48.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
(BCT) Long Term Investment Analysis (BCT:CA) - Stock Traders Daily
Published on: 2026-02-07 21:02:33 - baoquankhu1.vn
Published on: 2026-02-07 19:20:19 - baoquankhu1.vn
Market Recap: Does BriaCell Therapeutics Corp align with a passive investing strategyWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Published on: 2026-02-06 19:26:35 - baoquankhu1.vn
Published on: 2026-02-04 18:01:12 - baoquankhu1.vn
Stocks in play: BriaCell Therapeutics Corp. - Barchart.com
Big Picture: Should I buy BriaCell Therapeutics Corp Equity Warrant stock nowEarnings Recap Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
How does BriaCell Therapeutics Corp. Equity Warrant compare to its peersJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Will BriaCell Therapeutics Corp. stock hit new highs in YEAR2025 Risk Factors & AI Powered Trade Plan Recommendations - mfd.ru
What’s the profit margin of BriaCell Therapeutics Corp. Equity WarrantPortfolio Gains Summary & Weekly Top Stock Performers List - mfd.ru
BriaCell Brief: Says Patients' Images Show Regression And Resolution Of Metastasized Tumors And Immune Activation - marketscreener.com
(BCT) Equity Market Report (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment - GuruFocus
BriaCell Treatment Shows Significant Efficacy in Cancer Patients - Intellectia AI
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation - Sahm
Can BriaCell Therapeutics Corp. ride the EV waveJuly 2025 Pullbacks & Accurate Buy Signal Alerts - mfd.ru
BriaCell reports long-term survival data in metastatic breast cancer By Investing.com - Investing.com India
BriaCell Therapeutics Corp. - Baystreet.ca
BriaCell (BCTX) Reports Promising Phase 2 Survival Data - GuruFocus
BriaCell Therapeutics Says Phase 2 Metastatic Breast Cancer Patients Survival Data Exceed Benchmarks - marketscreener.com
BriaCell's New Therapy Significantly Extends Survival in Breast Cancer Patients - Intellectia AI
BriaCell reports long-term survival data in metastatic breast cancer - Investing.com
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients - The Manila Times
Growth Value: Is BriaCell Therapeutics Corp a defensive stockJuly 2025 Rallies & Step-by-Step Trade Execution Guides - baoquankhu1.vn
(BCT) Strategic Investment Report (BCT:CA) - Stock Traders Daily
Smart Money: Is BriaCell Therapeutics Corp Equity Warrant benefiting from innovation trendsLayoff News & Weekly Stock Breakout Alerts - baoquankhu1.vn
(BCT) Strategic Equity Report (BCT:CA) - Stock Traders Daily
(BCT) Stock Trading Blueprint (BCT:CA) - Stock Traders Daily
Is the Market Bullish or Bearish on BriaCell Therapeutics Corp? - Benzinga
Market Moves: Can BriaCell Therapeutics Corp Equity Warrant continue delivering strong returnsWeekly Trade Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
Surprises Report: Is Simpple Ltd stock a value trapJuly 2025 PostEarnings & Free Community Supported Trade Ideas - baoquankhu1.vn
ETF Watch: Does BriaCell Therapeutics Corp have a sustainable dividendMarket Risk Analysis & Verified Stock Trade Ideas - baoquankhu1.vn
The Globe’s stars and dogs for the week - The Globe and Mail
Philadelphia cancer therapy developer raises $30M amid signs of thaw in biotech funding - The Business Journals
Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch - RTTNews
BriaCell Therapeutics Announces Closing of US$30 million Public Offering - The Manila Times
BriaCell closes $30 million public offering to fund cancer immunotherapy By Investing.com - Investing.com Nigeria
BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit - MSN
BriaCell Therapeutics Completes $30 Million Public Offering - TipRanks
BriaCell closes $30 million public offering to fund cancer immunotherapy - Investing.com India
BriaCell Therapeutics Signs Multiple Material Agreements - TradingView
Why did BCTX stock surge 50% today? - MSN
BriaCell Therapeutics shares sink after $30 million capital raise - MSN
Market Review: Whats the profit margin of BriaCell Therapeutics Corp Equity Warrant2025 Pullback Review & Long-Term Growth Stock Strategies - baoquankhu1.vn
Quarterly Risk: What is the next catalyst for BriaCell Therapeutics CorpJuly 2025 Weekly Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
BriaCell Raises $30 Million Through Public Offering of Units and Listed Warrants - The Globe and Mail
Market Trends: Does BriaCell Therapeutics Corp Equity Warrant stock have upside surprise potentialGDP Growth & Stock Market Timing Techniques - baoquankhu1.vn
Aug Catalysts: What is BriaCell Therapeutics Corp Equity Warrants valuation compared to sectorWeekly Profit Analysis & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
U.S. Retail Sales Rise 0.6% MoM, Tech Stocks Decline - Intellectia AI
Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November - Benzinga
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):